Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bile acid-CoA:amino acid N-acyltransferase (BAAT) is a cytosolic, liver-predominant enzyme that catalyzes the conjugation of bile acids (mainly cholic acid and chenodeoxycholic acid) to the amino acids glycine and taurine, a critical step in bile acid metabolism and homeostasis. This amidation increases the detergent properties of bile acids in the gastrointestinal tract, facilitating the absorption of dietary fats and fat-soluble vitamins. BAAT is encoded by the BAAT gene (chromosome 9q22.3-9q31.1) and plays a role in the regulation of bile acid pool characteristics and enterohepatic recycling. Recent findings indicate a broader role in the synthesis of N-acyl taurines, a class of bioactive lipids implicated in glucose and lipid metabolism. Deficiency or genetic defects in BAAT can lead to disorders of bile acid metabolism, with clinical manifestations related to impaired bile flow, fat malabsorption, and hepatic dysfunction
Substrate for bile acid conjugation (glycine, taurine); Modulation of bile acid pool composition (potentially relevant for drugs altering bile acid metabolism)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bile acid-CoA:amino acid N-acyltransferase (BAAT).